Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021 · Nature Communications · 288 citations
https://doi.org/10.1038/s41467-021-26239-2
J
Jennifer Hammond
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
3.4K
Citations
29
h-index
53
i10-index
Jennifer Hammond is an academic researcher from Morgan Stanley Children's Hospital. The author has contributed to research in topics: COVID-19 Clinical Research Studies & SARS-CoV-2 and COVID-19 Research & Autism Spectrum Disorder Research. The author has an h-index of 29, co-authored 96 publications.
ORCID: 0000-0003-0809-3953Papers by this author
worksNirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
2024 · New England Journal of Medicine · 120 citations
https://doi.org/10.1056/nejmoa2309003
Therapeutics for COVID-19
2023 · Nature Microbiology · 102 citations
https://doi.org/10.1038/s41564-023-01356-4
Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
2024 · New England Journal of Medicine · 27 citations
https://doi.org/10.1056/nejmoa2309002
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial
2024 · Clinical Infectious Diseases · 10 citations
https://doi.org/10.1093/cid/ciae551
Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study
2024 · Drugs - Real World Outcomes · 3 citations
https://doi.org/10.1007/s40801-024-00422-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat